Relieving immunosuppression during long-term anti-angiogenesis therapy using photodynamic therapy and oxygen delivery
Relieving immunosuppression during long-term anti-angiogenesis therapy using photodynamic therapy and oxygen delivery
复制标题
使用光动力疗法和氧气输送缓解长期抗血管生成治疗期间的免疫抑制
DOI：
10.1039/d0nr02750b
复制
发表时间：
2020-07-21
期刊：
影响因子：
6.7
通讯作者：
Jin, Honglin
中科院分区：
文献类型：
--
作者：
He, Qianyuan;Zhang, Zhanjie;Jin, Honglin
血管生成是不可替代的肿瘤治疗靶点，而抗血管生成药物因其疏水性和低疗效而受到限制。更重要的是，肿瘤血管密度的长期关闭也会加剧缺氧，导致肿瘤微环境(TME)的免疫抑制。为了解决这些不足，我们开发了一种基于牛血清白蛋白纳米载体的单一治疗剂，它可以联合输送抗血管生成药物索拉非尼(S)和光敏剂Ce6(C)，以及基于二氧化锰(M)的分子氧气供应作为方便的一锅式纳米制剂(SCM@BSA)。与单一的抗血管生成治疗相比，SCM@BSA不仅可以改善抗血管生成药物的溶解性和治疗效果，而且还可以重塑抗血管生成治疗过程中免疫抑制的TME。综上所述，这些结果表明，SCM@BSA合成是一种非常简单的方法，可以解决长期抗血管生成治疗中经常遇到的缺点。
Angiogenesis is an irreplaceable therapeutic cancer target, where anti-angiogenesis are drugs that are limited by their hydrophobicity and low therapeutic effects. What is more, the long-term shutdown of tumor blood vessel density also aggravates hypoxia and causes immunosuppression in the tumor microenvironment (TME). In order to solve these shortcomings, we developed a single therapeutic agent based on a bovine serum albumin nanocarrier that can co-deliver the anti-angiogenic drug Sorafenib ("S") and the photosensitizer Ce6 ("C") along with a molecular oxygen supply based on MnO2("M") as a convenient one-pot formulated nanoscale agent (SCM@BSA). Compared with anti-angiogenesis monotherapy, SCM@BSA can not only improve upon the solubility and therapeutic effects of anti-angiogenesis agents, but it also reshapes the immunosuppressive TME during anti-angiogenic therapy. Together, these results point out that SCM@BSA synthesizedviaa very simple method can solve the shortcomings usually experienced during long-term anti-angiogenic therapy.